The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Jit, Mark; Mangen, Marie-Josée J.; Melliez, H.; Yazdanpanah, Yazdan; Bilcke, Joke; Salo, Heini; Edmunds, W. John; Beutels, Philippe

doi:10.1016/j.vaccine.2009.08.030

Cited by 92 publications

(78 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Uptake of this vaccine was generally slow and low in Europe [34]. Decision-makers waited for evidence to appear from the countries that started vaccinating as soon as European marketing authorisation was granted in May 2006, and they expected an important cost reduction for the vaccine because of the marginal benefit demonstrated through modelling exercises [35]. So, evidence of disease reduction was not enough.…”

Section: The Cauliflower Value Toolboxmentioning

confidence: 99%

3. How comprehensive can we be in the economic assessment of vaccines?

Standaert

Rappuoli²

2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

In two previous papers we argued on current vaccines economic assessment not fully comprehensive when using the incremental cost-utility analysis normally applied for treatments. Many differences exist between vaccines and drug treatments making vaccines economic evaluation more cumbersome. Four challenges overwhelmingly present in vaccines assessment are less important for treatments: requirements for population, societal perspectives, budget impact evaluation, and time focused objectives (control or elimination). Based on this, economic analysis of vaccines may need to be presented to many different stakeholders with various evaluation preferences, in addition to the current stakeholders involved for drugs treatment assessment. Then, we may need a tool making the inventory of the different vaccines health economic assessment programmes more comprehensive. The cauliflower value toolbox has been developed with that aim, and its use is illustrated here with rotavirus vaccine. Given the broader perspectives for vaccine assessment, it provides better value and cost evaluations. Cost-benefit analysis may be the preferred economic assessment method when considering substitution from treatment to active medical prevention. Other economic evaluation methods can be selected (i.e. optimisation modelling, return on investment) when project prioritisation is the main focus considered and when stakeholders would like to influence the development of the healthcare programme.

show abstract

Section: The Cauliflower Value Toolboxmentioning

confidence: 99%

3. How comprehensive can we be in the economic assessment of vaccines?

Standaert

Rappuoli²

2017

Journal of Market Access & Health Policy

View full text Add to dashboard Cite

show abstract

“…In several analyses, both the healthcare payer and societal perspectives were used, [33][34][35][36][37][38][39][40] whereas other studies were conducted from either a societal [41,42] or a healthcare payer perspective. [43] Two studies adopted a 'limited societal' perspective, which excluded indirect costs but included out-ofpocket medical expenses along with other direct medical costs. [44,45] Some studies focused only on RIX4414, [36,37,[42][43][44] while others also included indirect comparisons with the pentavalent rotavirus vaccine [34,35,38,39,41,45] or, in some cases, the universal rotavirus vaccination program being evaluated allowed for the use of either RIX4414 or the pentavalent rotavirus vaccine.…”

Section: Pharmacoeconomic Analyses Of Monovalent Rotavirus Vaccine Rimentioning

confidence: 99%

“…[43] Two studies adopted a 'limited societal' perspective, which excluded indirect costs but included out-ofpocket medical expenses along with other direct medical costs. [44,45] Some studies focused only on RIX4414, [36,37,[42][43][44] while others also included indirect comparisons with the pentavalent rotavirus vaccine [34,35,38,39,41,45] or, in some cases, the universal rotavirus vaccination program being evaluated allowed for the use of either RIX4414 or the pentavalent rotavirus vaccine. [33,40,45] A wide range of results was reported across the cost-effectiveness analyses, which appears to be related, at least in part, to the substantial heterogeneity among the models used in the studies.…”

Section: Pharmacoeconomic Analyses Of Monovalent Rotavirus Vaccine Rimentioning

confidence: 99%

“…The analyses typically showed that the cost of a universal rotavirus vaccination program was partly offset by reductions in RVGE-related healthcare resource use and that the program was associated with quality-adjusted life-year (QALY) gains. However, the universal rotavirus vaccination program was deemed to be cost effective from the perspective of the healthcare payer only in some studies, [36,37,42,43] but not in others, [33][34][35][38][39][40]43] when applying commonly reported cost-effectiveness thresholds, such as h20 000-50 000, $US50 000, or d20 000-30 000 per QALY gained. [46][47][48][49] A consistent finding across studies that were conducted from both a healthcare payer and a societal (or 'limited societal') perspective was that incremental cost-effectiveness ratios (ICERs) were more favorable from a societal perspective, [33][34][35][36][37][38][39][40]43] as might be expected because additional costs associated with RVGE (e.g.…”

Section: Pharmacoeconomic Analyses Of Monovalent Rotavirus Vaccine Rimentioning

confidence: 99%

“…[52,54] Two analyses of rotavirus vaccine RIX4414 included the effects of herd immunity, using data from dynamic transmission models in the sensitivity analyses, and in both cases the inclusion of herd immunity effects markedly improved ICER values. [35,43] …”

Section: Pharmacoeconomic Analyses Of Monovalent Rotavirus Vaccine Rimentioning

confidence: 99%

See 2 more Smart Citations

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries

Plosker¹

2012

Drugs R D

View full text Add to dashboard Cite

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

et al. 2010

View full text Add to dashboard Cite

Rotavirus Efficacy and Safety Trial (REST) enrolled nearly 70,000 infants, of whom more than 23,000 were from Finland. REST determined the efficacy of the pentavalent rotavirus vaccine (RV5) against rotavirus-related hospitalisations and emergency department (ED) visits in the first year after vaccination. Finnish infants initially in REST transitioned into the Finnish Extension Study (FES), where they were followed for rotavirus-related hospitalisations and ED visits through their second year of life and beyond. FES identified 150 (31%) additional rotavirus gastroenteritis (RVGE) cases beyond those identified in REST in the Finnish participants. Overall, RV5 reduced RVGE hospitalisations and ED visits, regardless of the rotavirus serotype, by 93.8% (95% confidence interval [CI]: 90.8–95.9%) for up to 3.1 years following the last vaccine dose. Vaccine efficacy against combined hospitalisations and ED visits between ages 4 months to 11 months, 12 months to 23 months, and 24 months to 35 months was 93.9% (95% CI: 89.1–96.9%), 94.4% (95% CI: 90.2–97.0%), and 85.9% (95% CI: 51.6–97.2%), respectively. The reduction of hospitalisations and ED visits due to any acute gastroenteritis, rotavirus or not, was 62.4% (95% CI: 57.6–66.6%) over the entire follow-up period. The results from FES confirm that RV5 induces high and sustained protection against rotavirus-related hospitalisations and ED visits, and has a very substantial impact on all gastroenteritis-related hospitalisations and ED visits into the third year of life in Finnish children.

show abstract

The cost-effectiveness of rotavirus vaccination: Comparative analyses for five European countries and transferability in Europe

Cited by 92 publications

References 23 publications

3. How comprehensive can we be in the economic assessment of vaccines?

3. How comprehensive can we be in the economic assessment of vaccines?

Pharmacoeconomic Spotlight on Rotavirus Vaccine RIX4414 (Rotarix™) in Developed Countries

Efficacy of the pentavalent rotavirus vaccine, RotaTeq®, in Finnish infants up to 3 years of age: the Finnish Extension Study

Contact Info

Product

Resources

About